Curated from over 6,000 chemically diverse ionisable lipids, the Invitrogen Vivofectamine Delivery Solutions can assist researchers and drug developers
Life science and clinical research company Thermo Fisher Scientific has unveiled the Invitrogen Vivofectamine™ Delivery Solutions to assist research by providing lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids.
Curated from over 6,000 chemically diverse ionisable lipids, this LNP portfolio addresses the challenge of delivering nucleic acids, such as RNA or DNA, to a target organ and cell type. This is often difficult to do without causing major side effects or destroying the nucleic acid’s integrity.
Invitrogen’s Vivofectamine Delivery Solutions offer two portfolios, each of which reduce the time and cost of research and drug development. The basic portfolio contains catalog LNP reagents for researchers and the drug development portfolio provides custom LNP reagents and services for drug developers.
Adaptable licensing terms are available to tailor to different drug developers’ needs. The Vivofectamine LNPs are available in a number of reagent formats as they were developed through iterative cycles of rational ionisable lipid design, synthesis, formulation optimisation, characterisation and in vitro and in vivo biological screening.
The Vivofectamine LNPs were also tested through multiple, escalated dosing and maximum tolerated dose regimes in non-human primate and rat studies. This testing included intramuscular delivery in prophylactic and cancer vaccines, systemic delivery to the liver, immune cells, muscles, as well as local delivery to tumours, eyes, adipose tissue and the central nervous system (CNS).
The results from these tests were compared to relevant clinical stage or approved drugs.
The LNP-delivered Covid-19 mRNA vaccines and growing safety concerns regarding viral delivery methods have increased the relevance of LNP delivery technology research in recent years.
LNP technology as an alternative to viral delivery methods is gaining traction particularly for prophylactic and cancer vaccines, gene replacement, gene editing therapies, stem cell therapies and in vivo and ex vivo immune cell therapies.
Earlier this year, Thermo Fisher Scientific launched the Axiom Pangenomix Array, its largest and most ethnically diverse to date and the only research solution offering four assays in one test.
